SecBot SecBot

BLRX

BioLineRx Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001498403 Biotech & Drug Discovery
$2.01 +0.00 (+0.00%)
Oct 27 4:00 PM ET · prev $2.01
Market cap
$10.3M
Nano cap
Median target
🔒 Subscribers only
1 year
−46.5%
from $3.76 · Oct 27
30 days
−17.3%
from $2.43
52-week range
$1.98–3.78
−47% from high · low Oct 19
Avg volume 20D
15.4K
Sep 30 spike 40.8K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Reddit crowd
60°
Warm · 1 mention this week
Filing reports
14
analyzed by SecBot
SecBot read BEARISH 9 reports · 90 days
Balance 6 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 6/9
Strongest BULLISH BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1 synergizes with multiple…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 3 trimmed or exited.

  • TrendDOWNTREND

    18% below its 50-day average.

  • SocialQUIET

    Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BNP PARIBAS FINANCIAL MARKETSTRIM500$1.6K
UBS Group AGNEAR_EXIT101$315.00
CITIGROUP INCNEAR_EXIT1$3.00
RHUMBLINE ADVISERSTRIM2,353$5.4K
UBS Group AGTRIM529$1.2K
UBS Group AGTRIM1,951$5.4K
MORGAN STANLEYNEAR_EXIT100$277.00
OSAIC HOLDINGS, INC.DOUBLED26$71.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2025

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Jun 17, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
May 30, 2025Jones Trading
UPGRADE
UPGRADEBuy
May 28, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Apr 2, 2025Jones Trading
DOWNGRADE
DOWNGRADEHold
Mar 31, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 25, 2024HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY-$3.14-$3.14–-$3.14+0.0%$1.6M
Next FY-$2.52-$2.52–-$2.52+0.0%$2.2M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 10, 2026
Press release
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical…
Aug 28, 2026
Offering
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage…
Jul 20, 2026
Press release
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical…
Mar 13, 2026
Clinical Trial
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Phase 3 · TERMINATED

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1 synergizes with multiple PARP…
6-K — Impact 5/10
Oct 5, 2026 SEC
The SEC declared BioLineRx's F-1 registration statement effective on October 2, 2026, enabling the resale of up to…
EFFECT — Impact 6/10
Sep 25, 2026 SEC
BioLineRx filed an F-1 registration statement to register 2,023,382 ADSs for resale by Armistice Capital, the sole…
F-1 — Impact 4/10
Sep 10, 2026 Other
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TAS
Aug 28, 2026 Press
BioLineRx announced a $3.75M registered direct offering and concurrent private placement, selling 1,348,921 ADSs at…
Impact 6/10
Jun 30, 2026 Inst.
BNP PARIBAS FINANCIAL MARKETS — TRIM
500 shares ($1.6K)
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
101 shares ($315.00)
Reddit
Crowd this week 60° Warm 1 bullish · 0 bearish
Mentions, 7 days 1 1 in posts · 0 in comments
Recent posts
r/pennystocks Bullish 4d ago
$BLRX - BioLineRx and Hemispherian Report GLIX1–PARP Inhibitor Synergy in HR-Proficient Ovarian Cancer
1 upvotes · 1 comments
All social signals and their track records

SecBot reports

14 filings · 1 press release · 5 bullish · 5 bearish · 2 mixed · 2 neutral
All BLRX filing & press-release reports (15)